Member Info for B2HS2L

Yeh, but I'm Spartacus.

Morning Shaun,
Well BioType is the one claiming :
"In addition to its production capabilities, Biotype GmbH provides its worldwide distribution network to bring the IVD assay to where it is urgently needed. Interested state examination institutes (LUA), test laboratories hospitals and independent test laboratories can order the test kit from Biotype via e-mail."
so I'd rather we were still working with BioType.

++++

http://primerdesign.co.uk/exsig/files/Path-exsig-COVID-19%20Direct-CE-STED%20IFU%20Issue%202.01.pdf

The Bruker FluoroCycler®XT (Bruker Hain Lifescience) is a valid PCR platform for use.
The assay has the CE-IVD mark, so good for Europe.
I believe this is a new platform with which to process an NCYT assay, and did not find it in the spreadsheet.

Wilson - Jim Mccarthy LinkedIn
Interests - BIOCOM:
About this group
We are the largest, most experienced leader and advocate for California’s life science sector. We work on behalf of more than 1,000 members to drive public policy, build an enviable network of industry leaders, create access to capital, introduce cutting-edge STEM education programs, and create robust value-driven purchasing programs.

Hmmm likey likey.

http://primerdesign.co.uk/exsig/files/Path-exsig-COVID-19%20Direct-CE-STED%20IFU%20Issue%202.01.pdf
The above 07 October 2020 Primerdesign assay Instructions for Use (not valid in USA), state that the Bruker FluoroCycler®XT (Bruker Hain Lifescience) is a valid PCR platform for use.
The assay has the CE-IVD mark, so good for Europe.

I found time tonight to re-read this 02.04.2020 press release from Biotype (Dresden):
https://www.biotype.de/en/company/news-events/news/pressemitteilung-02-04-2020.html
(in spreadsheet)

Surprised to read:

"...Biotype accepted the challenge and worked together with the British company Primerdesign Ltd. to produce a test system. Our goal was to be able to meet the high and still strongly growing demand for in-vitro diagnostic tests and to make as many tests available as possible," says Dr. Wilhelm Zörgiebel, managing partner of Biotype GmbH."

So Biotype are saying they assisted with the development of the qPCR test that FDA issued an EUA for on 23.03.2020.

Also another quote from same document:
"In addition to its production capabilities, Biotype GmbH provides its worldwide distribution network to bring the IVD assay to where it is urgently needed. Interested state examination institutes (LUA), test laboratories hospitals and independent test laboratories can order the test kit from Biotype via e-mail."

This relationship not RNS'd, but clearly growing in April this year.
It would be nice to get confirmation Biotype are still producing for us, and also some idea of their output.

++++

From 25 March 2020 RNS:

"...Primerdesign, its molecular diagnostics division, has signed a global distribution agreement for its COVID-19 test with Bruker-Hain Diagnostics, the molecular diagnostics products business unit of Bruker Corporation (Bruker).

Novacyt's real-time polymerase chain reaction (PCR) COVID-2019 IVD-CE test is validated for use on Bruker-Hain Diagnostics' GenoXtract® automated nucleic acid extraction device and associated extraction kits. It is under validation on Bruker's new FluoroCycler® XT PCR instrument, allowing Bruker to provide a full solution from automated extraction to result. Bruker has already initiated shipments of the Primerdesign test into Spain, France, Germany and UK."

A global distributor, with many instruments in European labs, but our assay not cleared for use with Bruker instruments in USA according to FDA EUA Instructions for Use.
https://www.fda.gov/media/136309/download

I assume that both relationships are ongoing.

ShaunP, - are you happy we are still accounting correctly for these global relationships in projections, or does it depend mostly on how these relationships have matured, for which we would need fresh info?

This is the most relevant info I can find Nick. Apologies if I haven't assisted with answering your question.
Re Mr Mullis and Mr Dyer long term incentive plan - from half year 2020 results RNS 17th Sep 2020:

"Novacyt granted to certain employees shares under a long-term management incentive plan adopted on 1 November 2017. The exercise price is set at the share price on the grant date and the options will be settled in cash. The options will fully vest on the third anniversary of the grant date. The payment expenses are calculated under IFRS 2 "Share-based payments". The accounting charge is spread across the vesting period to reflect the services received and a liability recognised on the statement of financial position."

Ref Hiring multiple candidates - Afterburner450 original post in thread:

https://www.indeed.co.uk/jobs?q=IT-IS%20International&from=vj&l=Middlesbrough&advn=4530652414183843&vjk=c39bdf16815d8f5a

Second vacancy down - Assembly Technician, IT-IS International Stokesley TS9 5JY:

This vacancy is based at the original address we have for IT-IS (1 WAINSTONES COURT, STOKESLEY BUSINESS PARK, Stokesley)
Using Google maps it was previously identified this facility had insufficient room for major output increase of instruments.

However, the below link (coroborated by other directory listings) identifies the IT-IS address as 1-3 WAINSTONES COURT, STOKESLEY BUSINESS PARK, an additional two (similar size) units.
https://addressesandpostcodes.co.uk/area/TS/TS9/TS9%205/TS9%205JY

Revisiting google maps ref we see all three units:
https://www.google.co.uk/maps/@54.463557,-1.1778392,3a,69.6y,235.27h,84.71t/data=!3m6!1e1!3m4!1sDIQYUQ5EzUkMtx0v7ohB7g!2e0!7i13312!8i6656

This does not give hope for a big increase in instrument output, but facility is three times bigger than originally thought.

The postcode for the soldering vacancy is unavailable, but for persons of suitable skill, it is possible they work from home, and the circuit boards are tested later.
That might free up some space at the TS9 5JY location, and the vacancy being advertised at TS9 5JY confirms original address is still in use.

Still doesn't feel like Chartwell have revolutionised production yet. - Still a work in progress?

KT - "Apart from the consumables maybe."

Everything in the picture comes out much clearer if the image is copied into 'Paint'.
All consumables, tests and manuals beside instrument have a POCKIT label.

Apologies Wilson, I did not check someone had already advised the newsletter.

Signing up to the Chartwell Autumn 2020 Newsletter gains access to an article about Novacyt,
and how Chartwell have assisted their client this year.
Nothing about IT-IS unfortunately.

Maybe some tips on roots?

Any chartists with info on Support & Resistance levels, or anything more juicy to share?

From a piece in the Times 26th May 2020. Payout over 3 years.

"Graham Mullis, the chief executive, was granted 1.1 million shares in November 2017 and Anthony Dyer, the chief financial officer, 376,643 under the so-called phantom long-term incentive plan. The performance shares are worth £3.6 million and £1.2 million, respectively."

Novacyt’s annual report states that the awards will vest on the third anniversary of the date of grant, subject to performance targets. Payment will be made in three equal tranches on the third, fourth and fifth anniversary of the date of grant, although each may be subject to the “company’s ability to make the payment”. In addition to Mr Mullis and Mr Dyer, a handful of employees are understood to have been granted shares, substantially fewer than the directors, under the scheme. Novacyt declined to comment.
++++

Now we know what GM will be doing with his bonus next November, and the November after, if he is still in charge of NCYT.

Luvely Jubbly Rodders, - GM's goin t'be a Biwyunair!

Evening Hillseeker, I posted some research a while back after seeing a video similar to the one you posted at 21:01
reference ( https://youtu.be/TEjNyhKlRD0 )

You get a glimpse of the instrument in use which I believe is made by analytikjena.

https://www.analytik-jena.com/knowledge/blog/posts/coronavirus-sars-cov-2-detection-workflow/

See paragraph 3 ref Amplification and Detection,
and Primerdesigns assay listed:
Primerdesign: 2019-nCoV genesig® Advanced kit***

*** Confirmed compatibility with qTOWER³

++++
analyticjena (German): Very large worldwide partnership network.
https://www.analytik-jena.in/company/partners/

Ailineboy, -

I believe they are playing for time.
Extra 2 days for the committee to ask
'When EXACTLY do you say this will be ready to roll out'?

Hamsters - replying to your

"Yes Bing007, I got an larger wheel and a elastic band in for back up."

Have you patented that yet?
Power companies will wanna know!!

BBC reported tonight that three other vaccines are in development along very similar lines to the Pfizer vaccine.

I suppose we should expect the MM's to act similarly should good news be forthcoming on these.

IMO the MM's knew what they were going to do with this way before a 'good news for Vaccines' report was announced.

II's will be happy for now, but there appetite will not be satisfied yet.

There is still a good deal of work to do before Pfizers vaccine is passed fit for use.

Trinity, - This is how NCYT can help out, reposted from yesterday as directly relevant:

With news of a virus mutation resulting apparently from the passing of COVID-19 from humans to Mink and back again, it might be in Novacyt's best interest to demonstrate to the world customers and medical authorities, that when the next Specificity report is issued, it states that Mink swabs have been tested, and our assay is capable of detecting this virus mutation.
I'm sure this opportunity has not been lost by the Primerdesign team who develop this report, and I look forward to such a statement being included in the next report.
As we are the only test manufacturer who provides this kind of report, we need to be seen to have tested the Mink virus mutation ASAP.

https://twitter.com/PrimerdesignLtd/status/1321007443418271744/photo/1

Silverback, I think a return to higher sp's will happen soon enough because there are only 70 million shares in circulation.
When II appetite returns, then sp will increase faster.
Tay has been expecting news from Microgen, and if that lands soon that will help.

You're right about winterplex and the flu differentiation.

The takeaway for me is:
"Successful validation of an initial range of newly developed Covid-19 lateral flow test kits was completed by the DHSC in September, allowing for orders to be placed".
So order placed in September.

Also:
"Where product has be sourced on an ex works basis it is imperative that this product is moved at the earliest opportunity to prevent it being sold to higher bidders."

Don't we have a contract? - or pirates are stealing the orders?